Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 20/20 | 0.81 |
| ▸ | EDNRA | P25101 | 20/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.60 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1068402 | 1.00 | EDNRB (0.81) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL8014408 | 0.93 | EDNRB (0.70) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| Darusentan SCHEMBL1068546 | 0.90 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| Darusentan SCHEMBL795084 | 0.90 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL15999837 | 0.89 | EDNRB (0.76) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| Darusentan SCHEMBL6895168 | 0.86 | EDNRB (0.80) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL6781616 | 0.86 | EDNRB (0.65) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL2352546 | 0.86 | EDNRB (0.81) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL2356501 | 0.86 | EDNRB (0.81) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL6708961 | 0.85 | EDNRB (0.64) | EDNRBEDNRANR1I2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040698-B2 | Method for preparing optically pure (+)-ambrisentan and (+)-darusentan | INSTITUTE OF CHEMISTRY CHINESE ACADEMY OF SCIENCES (CN) | 2015-05-26 | — | — | US | disclosed |
| US-20140256004-A1 | Process for the Preparation of an Endothelin Receptor Antagonist | CIPLA LIMITED (IN) | 2014-09-11 | — | — | US | disclosed |
| US-20140249309-A1 | Method for Preparing Optically Pure (+)-Ambrisentan and (+)-Darusentan | INSTITUTE OF CHEMISTRY CHINESE ACADEMY OF SCIENCES (CN) | 2014-09-04 | — | — | US | disclosed |
| EP-2768811-A1 | PROCESS FOR THE PREPARATION OF AN ENDOTHELIN RECEPTOR ANTAGONIST | Cipla Limited (IN) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013057468-A1 | PROCESS FOR THE PREPARATION OF AN ENDOTHELIN RECEPTOR ANTAGONIST | CIPLA LIMITED (IN) | 2013-04-25 | — | — | WO | disclosed |
| US-8404840-B2 | Process for the preparation of endothelin receptor antagonists | MSN LABORATORIES LIMITED (IL) | 2013-03-26 | — | — | US | disclosed |
| US-20110263854-A1 | Improved Process For The Preparation Of Endothelin Receptor Antagonists | MSN LABORATORIES LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
| EP-2350024-A2 | IMPROVED PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS | MSN Laboratories Limited (IN) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010070658-A2 | IMPROVED PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS | MSN LABORATORIES LIMITED (IN) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263854-A1 | Improved Process For The Preparation Of Endothelin Receptor Antagonists | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885NR1I2 2109/4885 |
| US-20140256004-A1 | Process for the Preparation of an Endothelin Receptor Antagonist | EDNRB, EDNRA, AGTR1 | EDNRB 1/4885EDNRA 2/4885NR1I2 520/4885 |
| US-20140249309-A1 | Method for Preparing Optically Pure (+)-Ambrisentan and (+)-Darusentan | AKR1D1, AKR1C2, AKR1C1 | EDNRB 47/4885EDNRA 30/4885NR1I2 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.